Bio Spec Overview
Ignite Creation Date:
2025-12-24 @ 9:08 PM
Last Modification Date:
2025-12-24 @ 9:08 PM
Retention:
SAMPLES_WITH_DNA
Description:
Peripheral blood samples will be collected at baseline (T0), 2 months (T2), and 4-5 months (T4) after initiation of omalizumab treatment. A total of 60 mL of peripheral blood will be obtained per timepoint: 10 mL in serum separator tubes for humoral studies, 10 mL in lithium heparin tubes for basophil activation test (BAT), and the remaining volume processed using Ficoll gradient for isolation and cryopreservation of peripheral blood mononuclear cells (PBMCs) in liquid nitrogen for future cellular and genomic analyses. Immunological assays include measurement of total and specific IgE and IgG4 to Pru p 3 and Pho d 2 (via ImmunoCAP), and basophil activation test (BAT) analyzed by flow cytometry. Samples may be used for further omics or genetic studies.
Section:
Peripheral blood samples will be collected at baseline (T0), 2 months (T2), and 4-5 months (T4) after initiation of omalizumab treatment. A total of 60 mL of peripheral blood will be obtained per timepoint: 10 mL in serum separator tubes for humoral studies, 10 mL in lithium heparin tubes for basophil activation test (BAT), and the remaining volume processed using Ficoll gradient for isolation and cryopreservation of peripheral blood mononuclear cells (PBMCs) in liquid nitrogen for future cellular and genomic analyses. Immunological assays include measurement of total and specific IgE and IgG4 to Pru p 3 and Pho d 2 (via ImmunoCAP), and basophil activation test (BAT) analyzed by flow cytometry. Samples may be used for further omics or genetic studies.